Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of …

R Riechelmann, V Srimuninnimit, P Kavan… - Annals of …, 2016 - annalsofoncology.org
Background The Ph 3 VELOUR study demonstrated that addition of aflibercept (ziv-
aflibercept [USA]) to fixed-dose FOLFIRI improved survival outcomes & response rates in …
被引用次数：6 相关文章

[引用][C] Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and …

R RIECHELMANN, V SRIMUNINNIMIT… - Annals of …, 2016 - observatorio.fm.usp.br
Observatório da Produção Intelectual: Aflibercept plus FOLFIRI for 2nd line treatment of
metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept …

[引用][C] Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and …

R Riechelmann, V Srimuninnimit… - Annals of …, 2016 - produccioncientifica.ucm.es
Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term
safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP) …